The study, published Sept. 2 in Molecular Cell, identifies a previously unrecognized role for CDK2 in shaping a tumor’s interaction with the immune system. In mice, blocking CDK2 helped immunotherapy drugs known as immune checkpoint inhibitors eradicate colorectal and breast tumors, including a form of triple-negative breast cancer that did not respond to immunotherapy alone.
“CDK2 inhibitors are being tested in clinical trials now, primarily in forms of ovarian and breast cancer known to require CDK2 for cancer cell growth,” said co-senior author Peter Sicinski, HMS professor of genetics at Dana-Farber. “But we’ve found that CDK2 inhibitors can be used in a way we did not expect, to overcome resistance to immune checkpoint inhibitors.”





